Etoposide and temozolomide in combination for the treatment of progressive small-cell lung cancer central nervous system metastases: two cases

Rimas V Lukas1, Janani Vigneswaran2, and Ravi Salgia3

1Department of Neurology, and 2Department of Medicine-Section of Hematology & Oncology, University of Chicago, Chicago, IL; 3University of Illinois, Urbana/Champaign, IL, USA

ABSTRACT

Introduction. Progression of central nervous system (CNS) metastases from small cell lung cancer (SCLC) after radiation therapy is associated with a poor prognosis.

Case reports. We present two cases of patients with progressive CNS metastases from SCLC treated with oral temozolomide and etoposide. Sustained clinical responses and radiographic stability were demonstrated. The palliative chemotherapy regimen was well tolerated.

Discussion. A regimen of oral temozolomide and etoposide for progressive CNS metastases from SCLC is well tolerated and may be associated with sustained stability of disease.

Key words: small cell lung carcinoma, neoplasm metastasis, central nervous system, etoposide, temozolomide, meningeal carcinomatosis.

Acknowledgments: Grant support: NIH/National Cancer Institute (5R01CA125541-03, 3R01CA125541-03S109, 5R01CA129501-02, 3R01CA129501-02S109, 5P01HL058064-140009), V-Foundation (Guy Gelded Memorial Foundation), Kate McMullen Foundation, Respiratory Health Association of Chicago, and Mesothelioma Applied Research Foundation (Jeffrey P Hayes Memorial Grant) (RS).

Conflict of interest statement: None declared.

Correspondence to: Rimas V Lukas, 5841 South Maryland Avenue, MC 2030, Chicago, Illinois 60637, USA. Tel +1-773-8349026; fax +1-773-7027485; email rlukas@neurology.bsd.uchicago.edu

Received February 27, 2012; accepted June 21, 2012.